Database : MEDLINE
Search on : Polymyositis [Words]
References found : 10378 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1038 go to page                         

  1 / 10378 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29522204
[Au] Autor:Hou Y; Luo YB; Dai T; Shao K; Li W; Zhao Y; Lu JQ; Yan C
[Ad] Address:Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
[Ti] Title:Revisiting Pathological Classification Criteria for Adult Idiopathic Inflammatory Myopathies: In-Depth Analysis of Muscle Biopsies and Correlation Between Pathological Diagnosis and Clinical Manifestations.
[So] Source:J Neuropathol Exp Neurol;, 2018 Mar 07.
[Is] ISSN:1554-6578
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The European Neuromuscular Centre (ENMC) pathological classification criteria of idiopathic inflammatory myopathies (IIMs) are debatable. The aim of this study was to explore their practicability and reproducibility. We conducted a retrospective analysis of 57 cases of IIMs excluding dermatomyositis (DM) and sporadic inclusion body myositis (sIBM) by in-depth analysis of muscle biopsies and comparisons of the clinical characteristics among polymyositis (PM), non-specific myositis (NSM) and necrotizing autoimmune myopathy (NAM). In 57 non-DM/sIBM-IIM cases, 25 were classified as PM, 15 as NSM, and 17 as NAM. Among them, 51 underwent multilevel sectioning examination of biopsies, with pathological changes at different levels warranting diagnostic rectification in 11 patients (21.57%): 4 PM were reclassified as NSM, and 7 NSM as NAM. Applying atypical CD8+ T cells surrounding non-necrotic muscle fibers resulted in diagnostic rectification from NSM to PM in 2 patients; using 20 T cells (instead of 10) as the threshold for the perivascular infiltration led to diagnostic rectification from NSM to NAM in 9 patients. There were no differences in disease duration or treatment outcomes among the subgroups. The strict pathological criteria to distinguish non-DM/sIBM-IIMs are of limited practicability and reproducibility, and may be of limited clinical significance.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1093/jnen/nly017

  2 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29516280
[Au] Autor:Gupta L; Chaurasia S; Srivastava P; Dwivedi S; Lawrence A; Misra R
[Ad] Address:Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, 226014, India.
[Ti] Title:Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults.
[So] Source:Clin Rheumatol;, 2018 Mar 07.
[Is] ISSN:1434-9949
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:We studied the serum levels of B cell survival factors BAFF and APRIL in patients with idiopathic inflammatory myositis (IIM) and their relation with clinical and autoantibodies. Seventy-five patients (51 females and 24 males) with IIM (Bohan and Peter's criteria 1975) and 25 healthy adults were analyzed for BAFF, APRIL and IL-17 by ELISA, and myositis-specific and associated antibodies (MSA and MAA) using line immunoblot assay. Of the 75 patients, 59 were adults, 42 had Dermatomyositis (DM), and 17 had Polymyositis. Median disease duration was 5 (3-12) months. BAFF levels were higher in IIM than healthy controls [p = 0.001], and in children with jDM than adults [p = 0.026]. BAFF levels were higher in adults with arthritis [p = 0.018], weight loss [p = 0.007], and PAH [p = 0.004]. Among the various MSAs, lowest levels were seen in those with anti-SRP [p = 0.043]. Median follow-up duration was 145 patient years. Twelve patients relapsed, while nine were in drug-free remission. BAFF were similar between these groups. Serum APRIL levels were elevated in limited number of patients with myositis, and the levels did not differ amongst the clinico-serologic phenotypes. IL-17 levels were higher in individuals positive for anti-SRP [p = 0.028]. Serum BAFF levels are elevated in IIM, more so in children. BAFF levels may be useful as biomarker for PAH and arthritis. Anti-SRP positivity is associated with elevated IL-17 levels suggesting role in pathogenesis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1007/s10067-018-4046-x

  3 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29447389
[Au] Autor:Bernstein EJ; Bathon JM; Lederer DJ
[Ad] Address:Department of Medicine, Columbia University Medical Center, New York, NY.
[Ti] Title:Survival of adults with systemic autoimmune rheumatic diseases and pulmonary arterial hypertension after lung transplantation.
[So] Source:Rheumatology (Oxford);, 2018 Feb 13.
[Is] ISSN:1462-0332
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives: Pulmonary arterial hypertension (PAH) is a major cause of morbidity and mortality in adults with systemic autoimmune rheumatic diseases (ARDs). The aim of this study was to determine whether adults with ARDs and PAH on right-sided heart catheterization (ARD-PAH) have increased mortality following lung transplantation compared with those with PAH not due to an ARD. Methods: We conducted a retrospective cohort study of 93 adults with ARD-PAH and 222 adults with PAH who underwent lung transplantation in the USA between 4 May 2005 and 9 March 2015 using data from the United Network for Organ Sharing. We examined associations between diagnosis and survival after lung transplantation using stratified Cox models adjusted for potential confounding recipient factors. Results: Among adults undergoing lung transplantation in the USA, we did not detect a difference in the multivariable-adjusted mortality rate between those with ARD-PAH and those with PAH [hazard ratio 0.75 (95% CI 0.47, 1.19)]. Conclusion: The presence of an ARD was not associated with increased mortality after lung transplantation in adults with PAH.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1093/rheumatology/kex527

  4 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29507032
[Au] Autor:Gameiro RS; Reis AIA; Grilo AC; Noronha C
[Ad] Address:Medicina Interna, Hospital Beatriz Ângelo, Loures, Portugal.
[Ti] Title:Following leads: connecting dysphagia to mixed connective tissue disease.
[So] Source:BMJ Case Rep;2018, 2018 Mar 05.
[Is] ISSN:1757-790X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Mixed connective tissue disease (MCDT) is a rare condition characterised by the presence of high titres of anti-U1 ribonucleoprotein antibodies and selected clinical features of systemic lupus erythematosus, systemic sclerosis and polymyositis/dermatomyositis. Early symptoms are non-specific, including easy fatigability, myalgia, arthralgia and Raynaud's phenomenon. Some reports emphasised the favourable outcome and excellent response to glucocorticoids, but there are contradictory studies reporting worse prognosis. Also, a subset of patients evolve into a clinical picture more consistent with a major diffuse connective tissue disease. We present the case of a 50-year-old black woman whose inaugural presentation of MCDT was oropharyngeal dysphagia, symmetrical proximal muscle weakness, tongue atrophy and skin sclerosis. High-dose corticosteroids and methotrexate were given with little improvement, maintaining disabling dysphagia leading to a percutaneous endoscopic gastrostomy tube placement. She was then started on intravenous immunoglobulin with progressive remission of symptoms.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:In-Process

  5 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29480875
[Au] Autor:Leatham H; Schadt C; Chisolm S; Fretwell D; Chung L; Callen JP; Fiorentino D
[Ad] Address:Department of Dermatology, Stanford University.
[Ti] Title:Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts.
[So] Source:Medicine (Baltimore);97(2):e9639, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The association between dermatomyositis and internal malignancy is well established, but there is little consensus about the methods of cancer screening that should be utilized.We wished to analyze the prevalence and yield of selected cancer screening modalities in patients with dermatomyositis.We performed a retrospective analysis of 2 large US dermatomyositis cohorts comprising 400 patients.We measured the frequency of selected screening tests used to search for malignancy. Patients with a biopsy-confirmed malignancy were identified. Prespecified clinical and laboratory factors were tested for association with malignancy. For each malignancy we identified the screening test(s) that led to diagnosis and classified these tests as either blind (not guided by suspicious sign/symptom) or triggered (by a suspicious sign or symptom).Forty-eight patients (12.0% of total cohort) with 53 cancers were identified with dermatomyositis-associated malignancy. Twenty-one of these 53 cancers (40%) were diagnosed within 1 year of dermatomyositis symptom onset. In multivariate analysis, older age (P = .0005) was the only significant risk factor for internal malignancy. There was no significant difference in cancer incidence between classic and clinically amyopathic patients. Twenty-seven patients (6.8% of the total cohort) harbored an undiagnosed malignancy at the time of dermatomyositis diagnosis. The majority (59%) of these cancers were asymptomatic and computed tomography (CT) scans were the most common studies to reveal a cancer.This is the largest US cohort studied to examine malignancy prevalence and screening practices in dermatomyositis patients. Our results demonstrate that, while undiagnosed malignancy is present in <10% of US patients at the time of dermatomyositis onset, it is often not associated with a suspicious sign or symptom. Our data suggest that effective malignancy screening of dermatomyositis patients often requires evaluation beyond a history, physical examination, and "age-appropriate" cancer screening-these data may help to inform future guidelines for malignancy screening in this population.
[Mh] MeSH terms primary: Dermatomyositis/complications
Dermatomyositis/diagnosis
Early Detection of Cancer
Neoplasms/complications
Neoplasms/diagnosis
[Mh] MeSH terms secundary: Adult
Dermatomyositis/epidemiology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasms/epidemiology
Prevalence
Retrospective Studies
Risk Factors
Time Factors
United States
[Pt] Publication type:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009639

  6 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28460448
[Au] Autor:Li L; Wang Q; Yang F; Wu C; Chen S; Wen X; Liu C; Li Y
[Ad] Address:Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
[Ti] Title:Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.
[So] Source:Oncotarget;8(16):26552-26564, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The presence of anti-MDA5 antibodies in serum represents an important biomarker in the diagnosis and prediction of prognosis for patients with idiopathic inflammatory myopathies (IIMs). Due to conflicting results that have been reported regarding the detection of anti-MDA5 antibodies, the goal of this study was to assess a potential association between the presence of anti-MDA5 antibodies and dermatomyositis/polymyositis (DM/PM), as well as the diagnostic and prognostic values of anti-MDA5 antibodies for DM/PM. For this, a review of literature published prior to October 15, 2016 was conducted. Eight studies with 286 PM patients and 216 healthy controls and nine studies with 628 DM patients and 221 healthy controls were selected according to specific inclusion criteria. The outcomes of these studies revealed that the presence of anti-MDA5 antibodies was associated with DM, especially CADM, and not with PM. Furthermore, the pooled sensitivity, specificity, and area under the curve (AUC) values were 0.62 (95% confidence interval (CI): 0.52-0.70), 1.00 (95% CI: 0.97-1.00), and 0.9381 for CADM patients versus healthy controls when an immunoprecipitation method was used. The presence of anti-MDA5 antibodies was also found to be significantly associated with an increased risk of death in DM (relative risk = 3.32, 95% CI: 1.65-6.67, P = 0.001). These findings suggest that anti-MDA5 antibodies correlate with DM and could be used as a biomarker in the clinical diagnosis of CADM. The presence of anti-MDA5 antibodies was also associated with poor prognosis regarding the overall survival of patients with DM.
[Mh] MeSH terms primary: Autoantibodies/immunology
Dermatomyositis/diagnosis
Dermatomyositis/immunology
Interferon-Induced Helicase, IFIH1/immunology
[Mh] MeSH terms secundary: Autoantibodies/blood
Biomarkers
Case-Control Studies
Disease Susceptibility
Enzyme-Linked Immunosorbent Assay
Female
Humans
Male
Odds Ratio
Prognosis
Reproducibility of Results
Risk
Sensitivity and Specificity
[Pt] Publication type:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Name of substance:0 (Autoantibodies); 0 (Biomarkers); EC 3.6.1.- (IFIH1 protein, human); EC 3.6.4.13 (Interferon-Induced Helicase, IFIH1)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15716

  7 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29496919
[Au] Autor:Bhansing KJ; VAN Rosmalen MH; VAN Engelen BG; VAN Riel PL; Pillen S; Vonk MC
[Ad] Address:Department of Rheumatology, Radboud University Medical Center; k.bhansing@reuma.umcn.nl.
[Ti] Title:Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis.
[So] Source:J Rheumatol;45(3):441-442, 2018 Mar.
[Is] ISSN:0315-162X
[Cp] Country of publication:Canada
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[St] Status:In-Data-Review
[do] DOI:10.3899/jrheum.171188

  8 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29289272
[Au] Autor:Shuker O; Khamaisi M
[Ad] Address:Internal Medicine Department, Institute of Endocrinology, Diabetes & Metabolism, Rambam Health Care Campus, Haifa, Israel; Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
[Ti] Title:When Patient/Family Expectations and Hospital Protocol Conflict.
[So] Source:Am J Med Sci;355(1):99-100, 2018 Jan.
[Is] ISSN:1538-2990
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Conflict (Psychology)
Family/psychology
Patient Transfer
Polymyositis
[Mh] MeSH terms secundary: Female
Humans
Male
Middle Aged
Polymyositis/psychology
Polymyositis/therapy
[Pt] Publication type:CASE REPORTS; EDITORIAL
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180101
[St] Status:MEDLINE

  9 / 10378 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29289262
[Au] Autor:Chen F; Li S; Wang T; Shi J; Wang G
[Ad] Address:Department of Rheumatology, China-Japan Friendship Hospital, Yinghua East Road, Chaoyang District, Beijing, China.
[Ti] Title:Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
[So] Source:Am J Med Sci;355(1):48-53, 2018 01.
[Is] ISSN:1538-2990
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The aim of this study was to compare the heterogeneity of interstitial lung disease (ILD) in patients with polymyositis and dermatomyositis (PM/DM) according to serological type. METHODS: A total of 182 patients with PM/DM-ILD were observed retrospectively. Antiaminoacyl-tRNA synthetase (ARS) and antimelanoma differentiation-associated gene5 (MDA5) antibodies were screened using immunoblotting approach. The patients with ILD were divided into 3 groups: MDA5 (with anti-MDA5 antibody), ARS (with anti-ARS antibody) and MSN (without anti-MDA5 or anti-ARS antibody) group. Pulmonary features, treatment responses and prognoses were compared among the groups. RESULTS: A higher percentage of rapidly progressive ILD (RP-ILD) occurrences (55.8% versus 25% versus 16.9%, P < 0.001) was observed in the MDA5 group compared to ARS and MSN groups. The MSN group experienced lower dyspnea (48.2% versus 79% versus 71.4%, P = 0.001) and fever (18.1% versus 39.5% versus 37.5%, P = 0.01) frequencies compared to MDA5 and ARS groups. Response to 6-month treatment among 95 patients showed highest deterioration ratio (70%, P = 0.001) of ILD in the MDA5 group. Additionally, the highest frequency of ILD improvement (60%, P = 0.04) was observed in the ARS group. During the observation period, 24 patients died of respiratory failure. The 5-year survival rates were significantly lower in MDA5 group (50.2%) compared to ARS group (97.7%) or the MSN group (91.4%) (P < 0.001). CONCLUSIONS: MDA5-ILD was associated with severe pulmonary manifestations, poor response to treatment and aggravated prognosis. The ARS-ILD group had favorable treatment response and prognosis. MSN-ILD patients had relatively worse treatment response and prognosis compared to the ARS group, even though they expressed milder pulmonary manifestation.
[Mh] MeSH terms primary: Autoantibodies/blood
Dermatomyositis/blood
Lung Diseases, Interstitial/blood
Polymyositis/blood
[Mh] MeSH terms secundary: Adult
Aged
China/epidemiology
Dermatomyositis/diagnosis
Dermatomyositis/mortality
Female
Humans
Lung Diseases, Interstitial/diagnosis
Lung Diseases, Interstitial/epidemiology
Male
Middle Aged
Polymyositis/diagnosis
Polymyositis/mortality
Retrospective Studies
Survival Rate/trends
[Pt] Publication type:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Autoantibodies)
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180101
[St] Status:MEDLINE

  10 / 10378 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29208264
[Au] Autor:Mohan V; Cherian SV
[Ad] Address:Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas. Electronic address: Vishnu.Mohan@uth.tmc.edu.
[Ti] Title:Spontaneous Pneumomediastinum in Dermatomyositis.
[So] Source:Am J Med Sci;354(6):e11, 2017 Dec.
[Is] ISSN:1538-2990
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Dermatomyositis/diagnostic imaging
Dermatomyositis/etiology
Mediastinal Emphysema/diagnostic imaging
Mediastinal Emphysema/etiology
[Mh] MeSH terms secundary: Female
Humans
Middle Aged
Vomiting/complications
Vomiting/diagnostic imaging
[Pt] Publication type:CASE REPORTS; LETTER
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171207
[St] Status:MEDLINE


page 1 of 1038 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information